Early Breast Cancer-Quality of Life after Switching from Tamoxifen to Exemestane Results of a Non-interventional Study

被引:2
作者
Bossart, M. [1 ]
Beussel, S. [1 ]
Hadji, P. [2 ]
Hasenburg, A. [1 ]
机构
[1] Univ Frauenklin, D-79106 Freiburg, Germany
[2] Univ Marburg, Marburg, Germany
关键词
early breast cancer; quality of life; endocrine therapy; tamoxifen; exemestane; POSTMENOPAUSAL WOMEN; AROMATASE INHIBITORS; RANDOMIZED-TRIAL; OF-LIFE; ENDOMETRIAL ASSESSMENT; CONTINUED TAMOXIFEN; ADJUVANT THERAPY; ANASTROZOLE; METAANALYSIS;
D O I
10.1055/s-0031-1280244
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose: The side effects of adjuvant endocrine therapy for breast cancer can have a negative impact on patients' quality of life (QoL) and reduce patient compliance. The purpose of this non-interventional trial was to evaluate the quality of life (QoL), adverse events and tolerance of therapy with exemestane after switching from tamoxifen to exemestane. Material and Methods: A total of 924 postmenopausal patients receiving exemestane after tamoxifen from 735 German centers participated in this non-interventional trial (NIT). During 1 year of exemestane treatment (25 mg p.o. daily, Aromasin (R)) QoL was assessed using the IBCSG (International Breast Cancer Study Group) QoL core questionnaires (IBCSG QOL modules 24-26, SF-12). Side effects and tolerance were evaluated. Results: Subjects receiving exemestane following 2-3 years of treatment with tamoxifen experienced a significant improvement in both general and breast cancer-related QoL during the first year on exemestane. A significant improvement in physical and mental health was assessed using the SF (Short Form) 12 questionnaire. Exemestane was considered safe and was generally well tolerated, with a low percentage of treatment-related adverse effects (AEs). The most common treatment-related AEs were arthralgia (2.4%) and bone pain (1.1%). With the exception of arthralgia, all AEs covered in the IBCSG-QOL module-24-26 questionnaire improved during the NIT. Arthralgia increased only slightly in the NIT. Conclusion: General and breast cancer-related QoL improved in the first year of treatment with exemestane after tamoxifen treatment.
引用
收藏
页码:847 / 852
页数:6
相关论文
共 31 条
[1]  
*AGO, EMPF KOMM MAMM
[2]  
[Anonymous], INTERDISZIPLINARE S3
[3]  
Baum M, 2002, LANCET, V359, P2131
[4]   Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach [J].
Bernhard, J ;
Hurny, C ;
Coates, AS ;
Peterson, HF ;
CastiglioneGertsch, M ;
Gelber, RD ;
Goldhirsch, A ;
Senn, HJ ;
Rudenstam, CM .
ANNALS OF ONCOLOGY, 1997, 8 (09) :825-835
[5]  
BERTELLI G, 2007, 30 ANN SAN ANT CANC
[6]  
BLISS JM, 2009, ANN SAN ANT BREAST C
[7]   Meta-analysis of vascular and neoplastic events associated with tamoxifen [J].
Braithwaite, RS ;
Chlebowski, RT ;
Lau, J ;
George, S ;
Hess, R ;
Col, NF .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2003, 18 (11) :937-947
[8]   Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations [J].
Coleman, R. E. ;
Bolten, W. W. ;
Lansdown, M. ;
Dale, S. ;
Jackisch, C. ;
Merkel, D. ;
Maass, N. ;
Hadji, P. .
CANCER TREATMENT REVIEWS, 2008, 34 (03) :275-282
[9]   A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [J].
Coombes, RC ;
Hall, E ;
Gibson, LJ ;
Paridaens, R ;
Jassem, J ;
Delozier, T ;
Jones, SE ;
Alvarez, I ;
Bertelli, G ;
Ortmann, O ;
Coates, AS ;
Bajetta, E ;
Dodwell, D ;
Coleman, RE ;
Fallowfield, LJ ;
Mickiewicz, E ;
Andersen, J ;
Lonning, PE ;
Cocconi, G ;
Stewart, A ;
Stuart, N ;
Snowdon, CF ;
Carpentieri, M ;
Massimini, G ;
Bliss, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) :1081-1092
[10]   Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen [J].
Dowsett, Mitch ;
Cuzick, Jack ;
Ingle, Jim ;
Coates, Alan ;
Forbes, John ;
Bliss, Judith ;
Buyse, Marc ;
Baum, Michael ;
Buzdar, Aman ;
Colleoni, Marco ;
Coombes, Charles ;
Snowdon, Claire ;
Gnant, Michael ;
Jakesz, Raimund ;
Kaufmann, Manfred ;
Boccardo, Francesco ;
Godwin, Jon ;
Davies, Christina ;
Peto, Richard .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :509-518